This site contains research compounds intended for laboratory and research use only. Please confirm you are 21 or older and agree to our research-use terms.
I am under 21 / exitFor research use only. Not for human consumption.
A 39-amino-acid incretin-class triagonist supplied as a lyophilized powder. HPLC-verified at ≥99% purity with a batch-specific certificate of analysis on every lot.
Per vial, with the 20% new-customer welcome applied at checkout.
Choose quantity
View the 10 mg lab certificate (PDF)Most incretin-class peptides studied to date act on one or two receptors. Retatrutide is structurally notable because a single molecule carries agonist activity at three.
The incretin system is a set of gut-derived hormone signals that participate in glucose regulation and energy metabolism. Research peptides in this class are designed to bind and activate specific receptors in that system. A mono-agonist targets one receptor; a dual agonist targets two. Retatrutide is designed as a triagonist — one peptide chain with activity at three distinct receptor targets.
That matters to researchers for a practical reason: comparing a triagonist against mono- and dual-agonist compounds isolates what the third receptor contributes, which is difficult to study by combining separate molecules with different pharmacokinetics.
Glucagon-like peptide-1 receptor. The most extensively characterised incretin target, and the basis of the single-agonist peptide class that preceded this one.
Glucose-dependent insulinotropic polypeptide receptor. The second incretin axis, and the addition that defines the dual-agonist generation of research compounds.
The third axis, and the one that distinguishes a triagonist. Glucagon receptor signalling sits on the opposing side of glucose regulation from the incretin receptors, which is why combined activity in a single molecule is of structural interest.
Retatrutide is an investigational compound. It has not been approved by the FDA or any comparable regulator for any use. The following peer-reviewed publications are provided so researchers can locate the primary literature directly. They are cited as literature — APEX 100 Research makes no claim about outcomes, efficacy or suitability for any purpose.
Later-stage trials of this compound are ongoing. Trial records are searchable on ClinicalTrials.gov under the development code LY3437943.
Volume pricing applies automatically at checkout. Prices shown include the 20% new-customer welcome discount.
GLP-3 RTA is our catalogue designation for this research material. The compound is retatrutide, development code LY3437943. CAS 2381089-83-2.
High-performance liquid chromatography separates the sample into its components and measures each as a proportion of the total. ≥99% means the target peptide accounts for at least 99% of the material by that method. The chromatogram showing this is included in the lot’s COA.
Yes. Sample documentation is on our COA page, and we will send the specific COA for any lot on request — before or after purchase.
No. Retatrutide is investigational. It has not been approved by the FDA or any comparable regulator for any use. It is supplied here strictly as a research material.
Sourced and shipped within the United States, typically 2-day delivery. Lyophilized peptides are stable in transit; refrigerate on arrival.
Mass of lyophilized compound per vial. Both are the same material to the same ≥99% specification, with the same documentation. The 30 mg vial carries a lower cost per milligram.
Every lot is tested before release and ships with its own certificate of analysis. We publish the COA unredacted — including the lot number, the test date and the actual chromatogram — rather than a summary figure.
High-performance liquid chromatography establishes purity against the ≥99% specification. The chromatogram is included in the COA, not just the resulting number.
Identity is confirmed by mass spectrometry against the expected molecular weight of 4731.33 g/mol.
Each vial’s lot number corresponds to a specific COA on file. Request the document for any lot you have received at any time.
| Compound | Retatrutide (development code LY3437943) |
|---|---|
| Class | Incretin-class triple receptor agonist |
| CAS number | 2381089-83-2 |
| Molecular formula | C221H342N46O68 |
| Molecular weight | 4731.33 g/mol |
| Peptide length | 39 amino acids |
| Physical form | Lyophilized powder, white to off-white |
| Purity | ≥99% by HPLC |
| Identity confirmation | Mass spectrometry |
| Vial sizes | 10 mg (SKU A100-RT10) · 30 mg (SKU A100-RT30) |
| Storage | Lyophilized: 36–46 °F. Long term: −4 °F, protected from light |
| Documentation | Batch-specific COA, unredacted, retained on file per lot |
Supplied lyophilized. Standard laboratory handling for peptides of this class applies.
| Lyophilized storage | 36–46 °F short term; −4 °F for extended storage, protected from light |
|---|---|
| Reconstitution | Bacteriostatic water is the common choice for laboratory reconstitution. Add solvent slowly against the vial wall; do not inject directly onto the powder. |
| Mixing | Swirl gently until dissolved. Do not shake or vortex — mechanical agitation can shear peptide chains. |
| After reconstitution | Refrigerate at 36–46 °F. Avoid repeated freeze-thaw cycles. |
| Light | Protect from light at all stages. |
These are general laboratory handling notes for a lyophilized peptide. They are not a protocol, and nothing on this page constitutes a dosing recommendation of any kind.
Research use only. Not for human consumption.
All materials supplied by APEX 100 Research are intended exclusively for laboratory research by qualified professionals. They are not drugs, foods, cosmetics, or medical devices, and they are not intended to diagnose, treat, cure or prevent any disease or condition.
Nothing on this page is medical advice, a dosing recommendation, or a representation that this compound is safe or effective for any purpose. Retatrutide is an investigational compound that has not been approved for any use by the FDA or any comparable regulatory authority. Peer-reviewed publications are referenced above so researchers may consult the primary literature directly; their citation is not a claim about this material.
By purchasing, the buyer confirms they are a qualified researcher, are 21 years of age or older, and accept full responsibility for lawful handling, storage and use of the material.
